Quarterly Consolidated Statement Of Cash Flows

TAKARA BIO INC. - Filing #7300711

Concept As at
2024-09-30
2024-04-01 to
2024-09-30
As at
2024-03-31
As at
2023-09-30
2023-04-01 to
2023-09-30
As at
2023-03-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
427,000,000 JPY
1,588,000,000 JPY
Depreciation
1,839,000,000 JPY
2,132,000,000 JPY
Impairment losses
108,000,000 JPY
JPY
Amortization of goodwill
346,000,000 JPY
307,000,000 JPY
Increase (decrease) in allowance for doubtful accounts
0 JPY
-34,000,000 JPY
Interest expenses
10,000,000 JPY
12,000,000 JPY
Decrease (increase) in trade receivables
2,693,000,000 JPY
3,493,000,000 JPY
Decrease (increase) in inventories
-49,000,000 JPY
-218,000,000 JPY
Increase (decrease) in trade payables
-872,000,000 JPY
-463,000,000 JPY
Other, net
-384,000,000 JPY
-193,000,000 JPY
Subtotal
5,063,000,000 JPY
2,560,000,000 JPY
Interest and dividends received
151,000,000 JPY
89,000,000 JPY
Interest paid
-10,000,000 JPY
-11,000,000 JPY
Net cash provided by (used in) operating activities
6,099,000,000 JPY
2,087,000,000 JPY
Cash flows from investing activities
Other, net
0 JPY
-2,000,000 JPY
Net cash provided by (used in) investing activities
-396,000,000 JPY
-10,805,000,000 JPY
Cash flows from financing activities
Dividends paid
-2,046,000,000 JPY
-5,047,000,000 JPY
Other, net
0 JPY
JPY
Net cash provided by (used in) financing activities
-2,151,000,000 JPY
-5,126,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
1,500,000,000 JPY
851,000,000 JPY
Net increase (decrease) in cash and cash equivalents
5,052,000,000 JPY
-12,993,000,000 JPY
Cash and cash equivalents
38,223,000,000 JPY
33,171,000,000 JPY
36,065,000,000 JPY
49,058,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.